Amgen Drug Meets Primary Endpoint in Late-Stage Study
Amgen’s potential Sjogren’s disease treatment dazodalibep met the primary endpoint in a late-stage study.
Amgen’s potential Sjogren’s disease treatment dazodalibep met the primary endpoint in a late-stage study.